SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 1, 2000
-------------
Generex Biotechnology Corporation
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 82-049021
- ---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
- ---------------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
------------
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 1. Changes in Control of Registrant
The Registrant increased the size of its Board of Directors from four to
six members effective March 1, 2000. Iain Brown and William M. Hawke, M.D. were
elected directors of the Registrant to fill the vacancies thus created.
Iain Brown, age 59, has over forty years experience in banking and asset
management, and presently serves as Chief Executive Officer of Fidra Holdings
Ltd., an asset management firm located in Nassau, The Bahamas. From September
1989 to November 1997, Mr. Brown served as President of First National Bank,
Turks & Cacos Island. Prior to September 1989, he was employed in various
capacities with affiliates of Standard Chartered Bank in the Far East and
Europe, retiring in September 1987 as President and Chief Executive Officer of
Standard Chartered Bank Canada, headquartered in Toronto.
William M. Hawke, age 59, has approximately thirty years experience as a
medical researcher, educator and practitioner. Dr. Hawke presently is a
Professor in the Departments of Otolaryngology and Pathology at the University
of Toronto, and is on the staff of the Departments of Otolaryngology at St.
Joseph's Health Center, The Toronto Hospital and Mount Sinai Hospital, all
located in Toronto, Ontario.
The Registrant's Board of Directors also has formed an Audit Committee. Mr.
Brown and Dr. Hawke were elected to the Committee. The third member of the
Committee is E. Mark Perri, the Registrant's Chief Financial Officer, who is a
member of the Committee ex officio.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: March 1, 2000 By: /s/ E. Mark Perri
--------------- -------------------------------
E. Mark Perri, Chairman and CFO
